1	High diagnostic rate of whole genome sequencing in primary ciliary
2	dyskinesia
3	
4	
5	Holly A Black <sup>1,2</sup> , Sophie Marion de Proce <sup>1*</sup> , Jose L Campos <sup>3*</sup> , Alison Meynert <sup>3</sup> , Mihail Halachev <sup>3</sup> , Joseph
6	A Marsh <sup>3</sup> , Robert A Hirst <sup>4</sup> , Chris O'Callaghan <sup>4</sup> , Scottish Genomes Partnership, Javier Santoyo-Lopez <sup>5</sup> ,
7	Jennie Murray <sup>2,3</sup> , Kenneth Macleod <sup>6</sup> , Don S Urquhart <sup>6,7</sup> , Stefan Unger <sup>6,7</sup> , Timothy J Aitman <sup>1</sup> <sup>,</sup>
8	Pleasantine Mill <sup>3^</sup>
9	
10	<sup>1</sup> Centre for Genomic and Experimental Medicine, MRC Institute of Genetics and Cancer, University of Edinburgh,
11	Edinburgh, UK
12	<sup>2</sup> South East of Scotland Genetics Service, Western General Hospital, Edinburgh, UK
13	<sup>3</sup> MRC Human Genetics Unit, MRC Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK
14	<sup>4</sup> Centre for PCD Diagnosis and Research, Department of Respiratory Sciences, University of Leicester, UK
15	<sup>5</sup> Edinburgh Genomics, Edinburgh, UK
16	<sup>6</sup> Department of Paediatric Respiratory and Sleep Medicine, Royal Hospital for Sick Children, Edinburgh, UK
17	<sup>7</sup> Department of Child Life and Health, University of Edinburgh, Edinburgh, UK
18	* These authors contributed equally to the manuscript
19	<sup>^</sup> Joint senior authors
20	
21	Summary: Whole genome sequencing (WGS) yielded a high genetic diagnostic rate (100%) in eight Scottish
22	patients with clinically diagnosed primary ciliary dyskinesia (PCD) by detection of large structural variants,
23	homology modelling and identification of a novel disease gene with a dominant mode of inheritance. Prioritised
24	WGS may facilitate early genetic diagnosis in PCD.
25	

26

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

27

## 28

## 29 Abstract

Aim: Primary ciliary dyskinesia (PCD) is a genetic disorder affecting motile cilia. Most cases 30 are inherited recessively, due to variants in more than 50 genes that result in abnormal or 31 absent motile cilia. This leads to chronic upper and lower airway disease, sub-fertility and 32 laterality defects in some cases. Given overlapping clinical features and genetic 33 heterogeneity, diagnosis can be difficult and often occurs late. Of those tested, an estimated 34 35 30% of genetically screened PCD patients still lack a molecular diagnosis. Here, we aimed to 36 identify how readily a genetic diagnosis could be made in a clinically diagnosed population 37 using whole genome sequencing (WGS) to facilitate identification of pathogenic variants in known genes as well as identify novel PCD candidate genes. 38

Methods: WGS was used to screen for variants causing PCD in 8 clinically diagnosed PCD
 patients, sequenced as trios where parental samples were available.

<u>Results:</u> Seven of the eight cases (87.5%) had homozygous or biallelic variants in *DNAH5*, *DNAAF4* or *DNAH11* that were classified as pathogenic or likely pathogenic. Three of the variants were deletions, ranging from 3kb to 13kb, for which WGS identified precise breakpoints, permitting confirmation by Sanger sequencing. WGS yielded a high genetic diagnostic rate from this clinically diagnosed population, in part through detection of structural variants as well as identification of a *de novo* variant in a novel PCD gene *TUBB4B*.

47 <u>Conclusion:</u> A molecular diagnosis allows for appropriate clinical management for cases and 48 their families, including prediction of phenotypic features correlated to genotype. Here, WGS 49 uplifted genetic diagnosis in cases of clinically diagnosed PCD by identifying structural variants 50 and novel modes of inheritance in new candidate genes. Our study suggests that WGS could 51 be a powerful part of the PCD diagnostic toolkit to increase the current molecular diagnostic 52 yield from 70%. It provides important new insight into our understanding of fundamental 53 biology of motile cilia as well as of variation in the non-coding genome in PCD.

54

#### 55

## 56 Introduction

Primary ciliary dyskinesia (PCD, OMIM: PS244400) is a genetic disorder of motile cilia (1-3), 57 highly structurally organised organelles that project from the surface of the cells. Their 58 59 organised structure allows the cilia to beat in a coordinated manner to effectively propel fluids across the surface of the airways, brain ventricles and reproductive tracts. However, in 60 PCD, these cilia have an abnormal structure or function, resulting in static cilia, cilia that beat 61 in an uncoordinated manner, or a complete absence of cilia (2,3). This can result in a chronic 62 respiratory disease, due to impaired mucociliary clearance, as well as hydrocephaly, laterality 63 defects (e.g. situs inversus) and fertility defects in a subset of patients. PCD often presents at 64 birth as unexplained neonatal respiratory distress. Affected children then present with 65 66 variable clinical features including a daily wet cough, chronic respiratory tract infections, 67 rhinitis, sinusitis and otitis media. Over time, these can lead to debilitating long-term complications, including bronchiectasis and hearing impairment (1–6). 68

69

However, PCD is a heterogeneous disorder that has significant phenotypic overlap with other 70 71 genetic respiratory diseases, such as cystic fibrosis and primary immunodeficiency. The current clinical diagnostic work-up for suspected PCD cases requires a battery of highly 72 73 specialised tests (7,8). This includes detection of low nasal nitric oxide (nNO), as well as high-74 speed video microscopy (HSVM) to assess cilia beating pattern and frequency and transmission electron microscopy (TEM) to assess the cilia ultrastructure from a nasal brush 75 biopsy. Abnormalities identified in cilia structure and/or beating pattern or in the presence of 76 clinical features such as chronic oto-sinopulmonary symptoms can be used to confirm a 77 diagnosis of PCD (1,2,6,8,9). Access to diagnostic testing is limited to a small number of highly 78 specialised units in the UK. Families must travel for testing, often over long distances and 79 sometimes on multiple occasions. Even in those patients with a clinical diagnosis of PCD, 21% 80 had normal ciliary ultrastructure (10). Therefore, additional sensitive and accessible 81 diagnostic techniques acceptable to patients of all ages are required. 82

83

PCD is a genetically heterogeneous disorder. The majority of cases are autosomal recessively inherited, with over 50 genes currently associated with PCD (1,2,6,11,12). Mutations in these

genes account for approximately 70% of PCD cases screened, suggesting additional causal 86 genes exist and/or more complicated structural variants (SVs) are being missed in known 87 genes (13). The genes associated with PCD encode proteins involved in cilia structure, cilia 88 89 assembly or regulatory complexes. There is often a correlation between the affected gene 90 and the defects in cilia motility or ultrastructure observed at diagnosis (1,6,7,9). However, this 91 is not always the case: it is estimated that 9-20% of PCD cases have normal or inconclusive ultrastructure by TEM (14). Similarly normal or non-diagnostic HSVM results complicate 92 diagnosis for a significant portion of known PCD genes (15). nNO is also considered a useful 93 94 screening test prior to referral for nasal brushing. While low nNO measurements may be 95 indicative of PCD in patients lacking clear ultrastructural defects, its use, particularly in young 96 children, has not been universally rolled out across PCD centres (16,17) and patients with mutations in at least some PCD genes show normal nNO levels (18,19). In such suspected 97 98 cases, where a clinical diagnosis is unclear, a genetic diagnosis is an important means to 99 confirm PCD (1,5,6,20). However, genetic testing often occurs late in the diagnostic work-up for PCD (7). Recent guidelines have recommended studies to investigate the utility of genetic 100 101 testing in the PCD diagnostic pathway, particularly as next generation sequencing (NGS) is 102 increasingly available (8,21,22).

103

In this study, we investigated the utility of whole genome sequencing (WGS) to detect 104 105 disease-causing variants in children and young adults with a clinical diagnosis of PCD. We selected a non-endogamous population where PCD was clinically confirmed to test whether 106 WGS could effectively improve the molecular diagnostic yield of PCD. WGS would provide 107 unbiased genome coverage beyond exons of ~50 genes associated with PCD whilst 108 simultaneously detecting a range of variants, from single nucleotide changes, small indels as 109 110 well as complicated SVs, which may be missed by targeted sequencing approaches. Eight patients were recruited, alongside parental samples where available. This led to a genetic 111 diagnosis for all eight cases, three of whom had a pathogenic deletion of 3 kb-13 kb and one 112 patient had a de novo missense variant p.P259L in a novel candidate gene TUBB4B. 113

114

115

#### 116 Materials and Methods

117 Patient cohort

Eight patients with a confirmed clinical diagnosis of PCD (50% female), aged 6 to 31 years, 118 were recruited to the study. Signed and informed consent was obtained from the affected 119 individual as well as relatives through approved protocols. Sample IDs were assigned and the 120 121 key known only those within the research group. Clinical phenotypes are shown in **Table 1**. 122 For details of blood samples, DNA extraction, and analysis of sample ethnicity see Supplementary Methods and Supplementary Figure 1. The study was approved by the 123 London-West London and Gene Therapy Advisory Committee Research Ethics Committee 124 (REC number 11/LO/0883). 125

126

## 127 Whole Genome Sequencing

DNA was sequenced by WGS at Edinburgh Genomics. Libraries were prepared using the Illumina TruSeq PCR-free protocol and sequenced on the Illumina HiSeq X platform. The average yield per sample was 136 Gb, with mean coverage of 36x (range 33.9-38.3).

131

## 132 Gene Panel, data analysis and variant classification

A virtual gene panel of 146 genes was created, which included the known 'green' 34 PCD 133 genes plus 107 suspected ciliopathy genes that may have respiratory features based on the 134 135 PCD PanelApp panel (v1.14) with five additional genes identified in the literature (CFAP300, DNAH6, DNAJB13, STK36 and TTC25) (23–25). Analysis of variants was carried out as described 136 in Supplementary Methods. Additional analyses were carried out across the FOXJ1 locus for 137 Case 3, in whom no diagnostic variants were identified using the virtual gene panel. A 138 genome-wide expanded analysis identified a de novo missense mutation p.P259L 139 (chr9:g.137242994:C>T (hg38)) in the gene TUBB4B only in the patient, and not present in 140 either parent (26). 141

142

## 143 Modelling of whole exome sequencing data

A whole exome sequencing (WES)-like subset of the WGS data was obtained by extracting only the reads mapping to the regions in the TWIST Exome Capture Kit (using samtools v1.6) from the BAM file for each sample. WES CNV calling was performed by ExomeDepth (v1.1.15) as detailed in Supplementary Methods.

- 148
- 149 Homology modelling of DNAH11 and location of missense variants

5

A homology model of the C-terminal region of the DNAH11 motor domain (residues 3348-4504) was built using PHYRE2 (27,28). The effects of mutations in the C-terminal domain (CTD) (residues 4124-4504) on protein stability were modelled with FoldX (29). Sequences of human dynein genes were aligned with MUSCLE (30) and the sequence alignment was visualised with MView (31). Further details are given in the Supplementary Methods.

155

156

## 157 Results

Eight PCD patients were recruited to the study as six trios, one proband-mother duo and one
singleton (**Table 1**). All eight cases had a confirmed clinical diagnosis of PCD, following a nasal
brush biopsy. In all cases, nasal brushings were undertaken for clinical suspicion of PCD.
Presentations and phenotype severity were varied and are summarised in **Table 1**.

162

163 Using a virtual PCD panel approach to initially screen the WGS, we confirmed genetic diagnosis for seven of the eight cases (Table 2). Three cases had biallelic pathogenic and/or 164 likely pathogenic variants in the outer dynein arm heavy chain subunit gene DNAH5, which 165 has previously been shown to contribute to the largest proportion of PCD cases among 166 167 populations of European descent (1). Case 1 had a hemizygous nonsense variant (c.5281C>T, p.(Arg1761Ter)), inherited from the mother and previously reported in PCD cases (32,33), and 168 an overlapping 13kb deletion on the other allele, inherited from the father (Supplementary 169 Figure 3). Case 2 had two nonsense variants in DNAH5, c.3949C>T, p.(Gln1317Ter), which was 170 previously reported (34), and the c.5281C>T, p.(Arg1761Ter) variant. ddPCR was used to 171 phase the variants in Case 2 (Supplementary Figure 4). Case 4 had a single base pair deletion, 172 resulting in a frameshift and premature termination codon (PTC) (c.10815del, 173 174 p.(Pro3606Hisfs)), and a single base pair duplication, resulting in direct creation of a PTC (c.13458dup, p.(Asn4487Ter)), which were shown to be in trans through trio-based phasing. 175 176 Both variants have been reported previously in PCD cases (33). All three cases with biallelic variants in DNAH5 were shown to have absence or defects of outer dynein arms on TEM 177 (Figure 1), with Case 1 and Case 2 also shown to have static cilia (Table 1, Supplementary 178 Video 1). This is consistent with loss of DNAH5, which has been shown to result in outer 179 dynein arm truncation and immotile cilia (33). All three share a similar clinical phenotype, 180

181 with chronic wet cough, sinus problems and recurrent chest infections. Hearing loss was also182 noted in cases 2 and 4.

183

184 Two cases had likely pathogenic variants in the cytoplasmic axonemal dynein assembly factor 185 DNAAF4 (DYX1C1), necessary for assembly and/or stability of the inner and outer dynein arms (Table 2) (35). Case 5 had a homozygous 3.5kb deletion encompassing exon 7 of DNAAF4, 186 which was also heterozygous in the mother. There was no evidence of uniparental disomy 187 188 and, given Case 5 is also reported to have an affected sibling, it is likely the father also carries 189 the 3.5kb deletion, although the father's DNA was unavailable. This variant has previously 190 been reported in PCD (35). Ultrastructural analysis was consistent with previous reports for 191 DNAAF4 mutations, with reports of absent dynein arms (35) (Figure 1) and immotile cilia shown on HSVM. Case 6 had a maternally-inherited nonsense variant (c.856G>T, 192 193 p.(Glu286Ter)) and a paternally-inherited 3.1 kb deletion encompassing the last two exons of 194 DNAAF4, predicted to disrupt the C-terminal tetratricopeptide-like helical domain region (TPR) by deleting the final 71 amino acids, as well as the 3'UTR. We predict this allele to be 195 196 loss-of-function as the resulting transcript is predicted to be subject to nonsense-mediated decay. Case 6 has bronchiectasis with a recurrent need for antibiotics. He has no ear or 197 198 hearing problems and situs solitus.

199

200 A further two cases had pathogenic or likely pathogenic variants in the outer dynein arm heavy chain subunit DNAH11. Case 7 had a homozygous missense variant in DNAH11 (c.13373 201 202 C>T, p.(Pro4458Leu)) previously reported in PCD cases (36,37), at a low frequency in gnomAD and *in silico* predictions support pathogenicity (**Table 2**). There was sufficient evidence to 203 classify the variant as likely pathogenic using ACMG guidelines (38,39). Case 8 had a 204 205 heterozygous 2 bp deletion, resulting in a PTC (c.10221 10222del, p.(Cys3409Trpfs)), which was classified as pathogenic (Table 2). The second variant was a heterozygous missense 206 207 (c.13288G>C, p.(Gly4430Arg)). This variant is at a low frequency in gnomAD and in silico predictions support pathogenicity, but it has not previously been reported in PCD cases. As 208 the variant is in trans with the c.10221 10222del variant, shown by phasing with parental 209 samples, there is sufficient evidence to classify the variant as likely pathogenic (**Table 2**). Both 210 Case 7 and Case 8 were shown to have a normal cilia ultrastructure with a dysmotile 211 212 phenotype (Figure 1, Supplementary Video 2), consistent with loss of DNAH11, which

localises to the proximal portion of respiratory cilia (40). There is however phenotypic
variability between Case 7 (situs inversus with dextrocardia and recurrent chest infections)
and Case 8 (chronic wet cough and recurrent ear infections, with situs solitus).

216

The two missense variants in *DNAH11* both reside at the 3' C-terminal domain (CTD) of the axonemal dynein heavy chain. While there is no structure available for DNAH11, there are homologous structures of other dynein proteins. To investigate the effects of the *DNAH11* missense mutations on protein structure, we built a homology model of the DNAH11 motor domain. Both mutations occur within the CTD, on the outer side of the dynein motor dimer (**Figure 2A**) and are intriguingly very close to each other in three-dimensional space (**Figure 2B**), separated by only 4.2 Å.

224

225 Molecular modelling of the missense mutations using the program FoldX (29) predicts that 226 the Gly4430Arg should be extremely disruptive to protein structure, with a  $\Delta\Delta G$  of 10.9 227 kcal/mol. We also modelled all other CTD missense variants presented in the gnomAD v2.1 228 database (41) . Remarkably, out of 269 variants (**Supplementary Table 1**), Gly4430Arg has the 229 highest  $\Delta\Delta G$  and therefore is predicted to be the most damaging. Moreover, this position is 230 fully conserved across all human dyneins (**Figure 2C**). This strongly suggests that Gly4430Arg 231 is pathogenic due to its disruptive effects on protein structure.

232

In contrast to Gly4430Arg, Pro4458Leu is predicted to be relatively mild at a structural level, with a  $\Delta\Delta G$  of 1.1 kcal/mol, making it only the 65<sup>th</sup> most damaging out of 269 variants (**Supplementary Table 1**). However, this residue is highly conserved, existing as a proline across all human dyneins except DNAH1, where it is an alanine. Thus, while Pro4458 is unlikely to cause a severe destabilisation of protein structure, its remarkable proximity to Gly4430 combined with a moderate structural perturbation and high conservation are supportive of pathogenicity.

240

To assess whether the three deletion variants identified in Cases 1, 5 and 6 would have been identified using WES, as opposed to WGS, the WGS data was subsetted to create a WES-like dataset for each sample (**Supplementary Figure 2**). CNV calling using ExomeDepth was able to identify the *DNAH5* variant c.5272-955\_6197del p.(?) in both the proband and father for

Family 1. However, the deletion, which spans five exons and has a breakpoint within exon 37, was called as covering only 4 of the 5 affected exons in the proband. The single exon deletion of *DNAAF4* c.784-1037\_894-2012del p.(?) was identified for the proband in Family 5, where it is homozygous, but not in the heterozygous mother. The *DNAAF4* deletion c.1048-149\_\*1048del p.(?) identified in Family 6 was not detected in the proband or father, despite both carrying the variant.

251

The phenotype of Case 3 is particularly relevant as ultrastructural analysis revealed ciliary 252 253 agenesis (Supplementary Video 3), sometimes referred to as reduced generation of multiple 254 motile cilia (RGMC), a specific subtype of PCD. In addition, Case 3 has shunted hydrocephalus, 255 having undergone initial ventriculo-peritoneal (VP) shunt insertion neonatally, and a subsequent VP shunt revision as an adolescent. To date, few genes have been implicated in 256 257 this RGMC phenotype by recessive inheritance, CCNO (cyclin O) and MCIDAS (multicilin) 258 (42,43) but no pathogenic or potentially pathogenic variants were identified in either gene. Heterozygous de novo mutations in the master motile ciliogenesis transcriptional regulator 259 FOXJ1 were identified as the first autosomal dominant cause of a distinct PCD-like condition, 260 associated with chronic respiratory disease, laterality defects and hydrocephalus (18). Similar 261 262 cellular defects are observed with reduced apical docking of centrioles and fewer cilia, but a focused analysis revealed no identifiable pathogenic mutations in the FOXJ1 locus. An 263 expanded, whole genome analysis for SNP and indel candidates produced a very limited list 264 of variants (Supplementary Table 2). This included a de novo missense mutation p.P259L 265 (chr9:g.137242994:C>T (hg38)) in the gene TUBB4B only in the patient, and not present in 266 either parent or found on gnomAD 4.0 or other publicly available databases. Whilst 267 interpretation of pathogenicity from a single patient is limiting, as part of a large international 268 269 collaboration, we were able to identify a further eleven patients with PCD carrying TUBB4B variants identified by next-generation sequencing (NGS) (26). This included five patients with 270 271 PCD-only carrying the identical p.P259L (chr9:g.137242994:C>T) variant, one carrying a different missense p.P259S (chr9:g.137242993:C>T (hg38)) variant and one patient carried an 272 in-frame ten amino acid duplication p.F242 R251dup (chr9: g.137242941 137242970dup 273 (hg38)) (26). Moreover, we also identified a recurrent de novo TUBB4B variant four patients 274 with a p.P358S (chr9:g.137243290:C>T (hg38)) variant, who presented with features of both 275 276 PCD with Leber congenital amaurosis and sensorineural hearing loss. In-depth functional

analyses in cell and animal models confirmed pathogenicity and distinct dominant-negative
mechanisms of action to cause different disease presentations (26). In summary, our WGS
strategy was very effective at identifying a novel PCD disease gene with the first report of
dominant negative disease mechanisms.

- 281
- 282

283

## 284 Discussion

In this study, WGS of affected probands and family members led to a genetic diagnosis in all 285 eight PCD patients, representing 11 different mutations in 3 autosomal recessive PCD genes 286 and 1 de novo mutation in a novel autosomal dominant PCD candidate TUBB4B. In Case 3, a 287 patient with features of reduced generation of motile cilia and hydrocephalus, no pathogenic 288 variants would been identified in a panel-based approach, even with targeted sequencing of 289 290 potential candidates for known RGMC loci. The diagnostic rate of 100% in our small study is higher than previous reports, in which 60-70% of cases received a genetic diagnosis based on 291 292 the known PCD gene panels (1,5,12,13,20), 75% on extended NGS panels (44) and 68-94% by WES (45-48). 293

294

295 Next-generation sequencing (NGS) technologies continue to revolutionise rare genetics 296 research and clinical diagnostics, where the advantages of WES versus WGS are often fiercely debated. Cheaper in terms of costs of sequencing, analysis and data storage, WES is generally 297 298 preferred as a front-line diagnostic tool. WES, however, has several issues in terms of 299 evenness of genome coverage and sequence bias, particular for copy number variations 300 (CNV). In comparison, several studies have found more accurate variant calls as well as even and unbiased coverage of coding regions are generated by WGS (49,50). Our analysis was 301 focused on known and candidate PCD genes, screening simultaneously for single nucleotide 302 variants (SNVs), small indels and more complex SVs. In three cases, pathogenic deletions were 303 identified, ranging in size from 3kb to 13kb. Modelling of our WGS data to represent WES-like 304 305 data suggested that WES data would only have identified the deletion in one of these three 306 cases, in which the deletion was homozygous. Since our WES-like model has more uniform coverage than true WES data, our WES-like model could be considered more reliable for CNV 307

calling than real-life WES sequence. However, we acknowledge that our model is based on
 36X WGS data, whereas WES would be nearer 100X in practice but coverage does vary across
 commercial platforms. The ability to detect SVs in PCD is of importance and consistent with
 recent diagnostic guidelines for PCD, which highlighted that causal SVs and intronic mutations
 can be missed due to the large number and size of PCD genes (8,21). Further, WES would not
 have provided the precise breakpoint information that allowed confirmation of the three
 deletion variants by Sanger sequencing.

315

316 Where WGS was clearly advantageous was PCD disease gene discovery in patients without 317 biallelic variants in known genes or in the one recent example of autosomal dominant 318 inheritance (FOXJ1) or in the few cases of X-linked recessive inheritance (RPGR, PIH1D3, OFD1) (12). In Case 3, WES would have likely identified the de novo SNV in TUBB4B, as WES 319 panels identified SNVs in the other 11 TUBB4B patients (26). Here, the clear advantage of 320 321 WGS was to rule out potential non-coding alterations in the known RGMC PCD genes of known inheritance such as FOXJ1 modes as to quickly prioritise novel candidates in our first 322 proband. As such, a clear benefit of WGS, similar to WES, is that its findings are future-proof; 323 the data generated can be re-screened for PCD-causing variants identified subsequent to 324 325 genetic testing, if initial testing is inconclusive. However, only WGS will allow future analysis of non-coding genome for variations in regulatory elements such as of transcription factor 326 binding sites that may underlie a subset of unsolved PCD cases. 327

328

Whatever the modality, increased genetic testing for PCD is critical. Currently genetic testing 329 for PCD sits as an additional step to confirm diagnosis by both European and American 330 guidelines (8,21,22). As shown here, and elsewhere, genetic testing can accurately diagnose 331 332 PCD where standard clinical procedures are unavailable, impractical or inconclusive (45-47,51) Importantly, a delayed PCD diagnosis is associated with worse prognosis (52,53). A 333 clinical diagnosis of PCD requires specialised, invasive testing, and frequently necessitates 334 travel over considerable distances to specialist centres. These tests are unsuitable for critically 335 ill neonates and for those unable to travel or unwilling to undergo invasive testing. Genetic 336 testing for PCD may therefore have utility in the neonatal period or in infancy that may have 337 been preferred to the diagnostic odyssey of the patients in this study, where the age of 338 339 diagnosis was between 5 and 12 years. Suggested clinical criteria for genetic testing in PCD

could include term babies who become unwell at >12 hours of age with respiratory disease, 340 lobar collapse, situs inversus and/or an unexpectedly high or prolonged oxygen requirement 341 (54,55). Increasing availability, reducing costs and recognised clinical utility of NGS platforms 342 343 such as WGS in the neonatal and paediatric intensive care unit setting would be consistent 344 with such indications (50,51,54,56–59). Moreover, either WES or WGS would help rule out other confounding clinical presentations such as primary immune deficiency disorders (PIDs), 345 with overlapping symptoms of frequent, often severe, airway infections as well as recurrent 346 347 otitis media, and sinusitis (60–62). Both platforms are advantageous as they allow analysis of 348 all potential causative genes, known and novel, thus faster to keep up with recently reported 349 genes that may not yet be included on PCD-gene panels. Indeed such technologies may prove 350 to be more cost- and time-effective as providing a molecular diagnosis test for PCD than conventional clinical gene panels (45,46,48,63). A prospective study would appear to be 351 warranted, to define the optimum criteria for genetic testing and diagnostic yield in neonates 352 353 and older infants and children with respiratory symptomatology to help expedite PCD diagnosis. 354

355

356 While earlier genetic testing for PCD is clearly a priority, PCD also remains underdiagnosed. 357 PCD has an estimated incidence of 1 in 7,500 births, rising to 1 in 2,300 in endogamous populations (64,65). In North America, it is estimated that only 1,000 patients have a 358 confirmed diagnosis of PCD as opposed to the predicted ~25,000- 50,000 these rates would 359 suggest to be affected with PCD (66). Similar underdiagnosis is reported in the UK, where 360 these prevalence estimates suggest there should be at least 8,900 people with PCD in the UK; 361 less than a quarter of these are known to the NHS highly specialised PCD service (67). A large 362 portion of these missing patients are likely adult patients within primary care or 363 364 bronchiectasis clinics, as suggested by one study which found 12% of bronchiectasis patients had pathogenic variants in known motile ciliopathy genes (68). Increased genetic testing as a 365 first-pass diagnostic test in these suspected cases of PCD could be a way of controlling access 366 367 to more labour-intensive clinical and pathological diagnostic work-up in limited specialist centres. 368

369

PCD needs to enter the precision medicine era. A genetic diagnosis is key to improved patient
 prognosis as we better understand genotype-phenotype relations (69) and critically to being

trial-ready as much-needed genetic therapies come online (70,71). Increased genetic testing 372 is also being combined with a curated worldwide database, similar to that of CFTR2 for Cystic 373 Fibrosis (72), to enable a better understanding of these genotype-phenotype relations in PCD 374 375 called CiliaVar (73). Such a database will significantly facilitate interpretation of variants, of 376 which 21% has been suggested to be variants of unknown significance (VUS) (73). For 377 example, in Cases 7 and 8 in our study, structural modelling of the CTD of DNAH11 aided the assignment of pathogenicity of two missense variants, with one predicted to be detrimental 378 to protein stability and the second, in close proximity to the first, shown to be highly 379 380 conserved.

381

382 In conclusion, this study demonstrates the benefits of using WGS to obtain a genetic diagnosis for PCD, through its ability to detect SNVs and SVs simultaneously as well as detecting variants 383 384 in genes outwith current gene panels. The detection of multi-kilobase deletions in three of 385 the seven diagnosed cases highlights the need to detect SVs as part of the genetic testing for PCD. It also allowed rapid prioritisation of SNVs in novel candidate genes with dominant 386 modes of inheritance. Practically and financially, WGS would likely sit behind current standard 387 388 of care panel-based or WES diagnostic platforms. Given the high genetic diagnostic rate 389 observed here and elsewhere (44,45,47,48), we suggest that genetic testing should be an early step in the current diagnostic pathway for PCD, particularly in cases where nasal brush 390 biopsy is unavailable. By moving clinical and genetic diagnostic pathways in PCD earlier, 391 ideally to early life, we could have a transformative long-term reduction in morbidity with 392 393 access to specialist care and disease-modifying therapies commenced before permanent lung 394 damage.

395

396

## 397 Acknowledgements

We thank the PCD families who participated in this study and the UK PCD Family Support
Group for support; Dr Lee Murphy and colleagues at the Wellcome Trust Clinical Research
Facility; Edinburgh Genomics for sequencing and analysis; and the Brompton Hospital PCD
Diagnostic Service and South East Scotland Genetics Service for clinical support.

402

13

Support statement: The Scottish Genomes Partnership is funded by the Chief Scientist Office of the Scottish Government Health Directorates [SGP 1] and the MRC Whole Genome Sequencing for Health and Wealth Initiative (MC\_PC\_15080). We acknowledge support from the MRC (PM: MC UU 00007 14, MR Y015002 1); an MRC Career Development Award (MR M02122X 1) and Lister Prize Fellowship to JAM; an NHS Research Scotland fellowship to SU; and an NRS/R+D fellowship from the NHS Lothian R&D office to DU. **Competing interests:** We confirm that no competing interests. 



contrast, DNAH11 variants do not uniformly disrupt outer dynein arms (black arrowheads) in cilia 437 from nasal brush of case HG-007. Disruption of both inner and outer dynein arms (red arrowheads) is observed in DNAAF4 variants, as shown for HG-005. Scale bars = 100 nm.



proteins around the region where the missense mutations occur.

## **Table 1: Clinical details of PCD cases.**

Case number	Samples recruited	Sex	Ethnicity	Age at diagnosis	Age at recruitment	Ciliary ultrastructure	Cilia motility	(dqq) ONn	Current FEV1 (% predicted)	NRD	Chronic wet cough	Regular IV antibiotics	Recurrent infections	Rhinosinusitis	Bronchiectasis	Recurrent ear infection	Hearing loss	Situs inversus	Dextrocardia
1	Trio	F	EUR	11- 15	16-20	Absent outer dynein arms	Static cilia	<5	83	U	Y	N	Y	Y	N	Y	N	N	N
2	Proband only	М	EUR	6-10	11-15	Outer dynein arm defect	Static cilia	8.5	90	Y	Y	Y	N	Y	Y	Y	Y	N	N
3	Trio	F	EUR	11- 15	11-15	Ciliary agenesis	N/A	15.5	47	Y	Y	Y	Y	Y	Y	N	Y	N	N
4	Trio	М	EUR	0-5	6-10	Outer dynein arm defect	Static cilia	75	82	Y	Y	N	Y	Y	N	N	Y	N	N
5	Proband and Mother	F	EUR	11- 15	31-35	Complete absence of dynein arm	Static cilia	U	U	N	Y	U	Y	Y	Y	Y	N	N	N
6	Trio	Μ	EUR	U	21-25	Unknown	Unknown	8.5	62	U	Y	Y	Y	Y	Y	N	Ν	N	Ν
7	Trio	Μ	SAS	6-10	6-10	Normal	Dysmotile	49.5	87	Ν	Ν	Ν	Y	Y	U	Ν	Ν	Y	Y
8	Trio	F	EUR	6-10	11-15	Normal	Dysmotile	22	75	U	Y	N	Y	Y	Ν	Y	N	N	Ν

Y= yes; N= no; U= unknown; F= female; M= male; NRD= neonatal respiratory distress; nNO= nasal nitric oxide; ppb= parts per billion; FEV1=
 forced expiratory volume in one second; IV= intravenous; EUR= European; SAS= South Asian

Table 2: Genetic variants identified in PCD cases. Variants were classified according to the ACMG/ACGS guidelines (38,39); the criteria met for each variant
 are shown.

Case numbe r	Gene	Transcript	dbSNP ID	Variant(s)	Zygosity	gnomAD allele frequency (v4.0.0)	In silico predictions	ACMG/ACG S Classificatio n	ClinVar Accession Number
1	DNAH5	NM_001369.3	N/A	c.5272- 955_6197del p.(?)	Compound heterozygous	Absent <sup>a</sup>	N/A	P (PVS1, PM3, PP4)	SCV001334255
			rs148891849	c.5281C>T, p.(Arg1761Ter) (32– 34)		6x10 <sup>-5</sup>	N/A	P (PVS1, PM2, PM3_str, PP4)	SCV001334256
2	DNAH5	NM_001369.3	rs176950857 1	c.3949C>T, p.(Gln1317Ter)(74)	Compound heterozygous	1.6x10 <sup>-6</sup>	N/A	P (PVS1, PM2, PM3_str, PP4)	SCV001334257
			rs148891849	c.5281C>T, p.(Arg1761Ter)(32– 34)		6x10 <sup>-5</sup>	N/A	P (PVS1, PM2, PM3_str, PP4)	SCV001334256
3	TUBB4B	NM_006088.6	N/A	c.776C>T, p.(Pro259Leu) (26)	Heterozygous	Absent	Grantham Score 98 AlphaMissens e 0.998 (LP)	P (PS2, PM2, PP2, PP3)	SCV002770069. 1
4	DNAH5	NM_001369.3	rs397515540	c.10815del, p.(Pro3606Hisfs) (33)	Compound heterozygous	4.1x10 <sup>-4</sup>	N/A	P (PVS1, PM2, PM3_str, PP4)	SCV001334258
			rs775696136	c.13458dup, p.(Asn4487Ter) (33)	1	1.6x10 <sup>-4</sup>	N/A	P (PVS1, PM2, PM3_str, PP4)	SCV001334259

5	DNAAF4	NM_130810.4	N/A	c.784-1037_894- 2012del p.(?) (35)	Homozygous	2.5x10 <sup>-4 b</sup>	N/A	P (PVS1, PM3_str, PP4)	SCV001334260
6	DNAAF4	NM_130810.4	rs770136467	c.856G>T, p.(Glu286Ter)	Compound heterozygous	2.6x10 <sup>-5</sup>	N/A	P (PVS1, PM2, PP4)	SCV001334261
			N/A	c.1048- 149_*1048del p.(?)		Absent <sup>a</sup>	N/A	P (PVS1, PM3, PP4)	SCV001334262
7	DNAH11	NM_00127711 5.2	rs72658835	c.13373C>T, p.(Pro4458Leu) (36,37,47,51)	Homozygous	8.4x10 <sup>-5</sup>	Grantham Score 98 REVEL 0.377 (Uncertain) AlphaMissens e 0.625 (LP)	LP (PM2, PM3, PP3, PP4)	SCV001334263
8	DNAH11	NM_00127711 5.2	rs145054078 8	c.10221_10222del, p.(Cys3409Trpfs)	Compound heterozygous	1.5x10 <sup>-5</sup>	N/A	P (PVS1, PM2, PP4)	SCV001334264
			N/A	c.13288G>C, p.(Gly4430Arg) (75)		2x10 <sup>-6</sup>	Grantham score 125 REVEL 0.641 (Damaging) AlphaMissens e 0.813 (LP)	LP (PM1_sup, PM2, PM3_str, PP3, PP4)	SCV001334265

470 P= pathogenic; LP= likely pathogenic; N/A= not applicable. <sup>a</sup>absent from gnomAD SV and gnomAD CNV. <sup>b</sup>frequency from gnomAD SV.

л	7	2
- 4	1	3

## 474 **REFERENCES**

- Lucas JS, Davis SD, Omran H, Shoemark A. Primary ciliary dyskinesia in the genomics age.
   Lancet Respir Med. 2020 Feb;8(2):202–16.
- 477 2. Leigh MW, Horani A, Kinghorn B, O'Connor MG, Zariwala MA, Knowles MR. Primary Ciliary
  478 Dyskinesia (PCD): A genetic disorder of motile cilia. Transl Sci Rare Dis. 2019 Jul 4;4(1–2):51–
  479 75.
- Wallmeier J, Nielsen KG, Kuehni CE, Lucas JS, Leigh MW, Zariwala MA, et al. Motile
  ciliopathies. Nat Rev Dis Primers. 2020 Sep 17;6(1):77.
- 482 4. Damseh N, Quercia N, Rumman N, Dell SD, Kim RH. Primary ciliary dyskinesia: mechanisms
   483 and management. Appl Clin Genet. 2017 Sep 19;10:67–74.
- 484 5. Mirra V, Werner C, Santamaria F. Primary ciliary dyskinesia: an update on clinical aspects,
  485 genetics, diagnosis, and future treatment strategies. Front Pediatr. 2017 Jun 9;5:135.
- 486 6. Dunsky K, Menezes M, Ferkol TW. Advances in the diagnosis and treatment of primary ciliary
  487 dyskinesia: A review. JAMA Otolaryngol Head Neck Surg. 2021 Jun 17;
- Halbeisen FS, Shoemark A, Barbato A, Boon M, Carr S, Crowley S, et al. Time trends in
  diagnostic testing for primary ciliary dyskinesia in Europe. Eur Respir J. 2019 Oct 24;54(4).
- 490 8. Shoemark A, Dell S, Shapiro A, Lucas JS. ERS and ATS diagnostic guidelines for primary ciliary
  491 dyskinesia: similarities and differences in approach to diagnosis. Eur Respir J. 2019 Sep
  492 5;54(3).
- 493 9. Raidt J, Wallmeier J, Hjeij R, Onnebrink JG, Pennekamp P, Loges NT, et al. Ciliary beat pattern
  494 and frequency in genetic variants of primary ciliary dyskinesia. Eur Respir J. 2014
  495 Dec;44(6):1579–88.
- 496 10. Jackson CL, Behan L, Collins SA, Goggin PM, Adam EC, Coles JL, et al. Accuracy of diagnostic
  497 testing in primary ciliary dyskinesia. Eur Respir J. 2016 Mar;47(3):837–48.
- Horani A, Ferkol TW. Advances in the genetics of primary ciliary dyskinesia: clinical
  implications. Chest. 2018 Sep;154(3):645–52.
- Legendre M, Zaragosi L-E, Mitchison HM. Motile cilia and airway disease. Semin Cell Dev Biol.
   2021 Feb;110:19–33.
- 502 13. Knowles MR, Zariwala M, Leigh M. Primary Ciliary Dyskinesia. Clin Chest Med. 2016
  503 Sep;37(3):449–61.
- 504 14. Goutaki M, Pedersen ESL. Phenotype-genotype associations in primary ciliary dyskinesia:
  505 where do we stand? Eur Respir J. 2021 Aug 5;58(2).
- Shapiro AJ, Ferkol TW, Manion M, Leigh MW, Davis SD, Knowles MR. High-Speed
   Videomicroscopy Analysis Presents Limitations in Diagnosis of Primary Ciliary Dyskinesia. Am J
   Respir Crit Care Med. 2020 Jan 1;201(1):122–3.
- 509 16. Walker WT, Jackson CL, Lackie PM, Hogg C, Lucas JS. Nitric oxide in primary ciliary dyskinesia.
  510 Eur Respir J. 2012 Oct;40(4):1024–32.

Shapiro AJ, Josephson M, Rosenfeld M, Yilmaz O, Davis SD, Polineni D, et al. Accuracy of Nasal 511 17. 512 Nitric Oxide Measurement as a Diagnostic Test for Primary Ciliary Dyskinesia. A Systematic Review and Meta-analysis. Ann Am Thorac Soc. 2017 Jul;14(7):1184–96. 513 514 18. Wallmeier J, Frank D, Shoemark A, Nöthe-Menchen T, Cindric S, Olbrich H, et al. De Novo 515 Mutations in FOXJ1 Result in a Motile Ciliopathy with Hydrocephalus and Randomization of Left/Right Body Asymmetry. Am J Hum Genet. 2019 Nov 7;105(5):1030-9. 516 Raidt J, Krenz H, Tebbe J, Große-Onnebrink J, Olbrich H, Loges NT, et al. Limitations of Nasal 517 19. 518 Nitric Oxide Measurement for Diagnosis of Primary Ciliary Dyskinesia with Normal 519 Ultrastructure. Ann Am Thorac Soc. 2022 Aug;19(8):1275-84. 20. 520 Kurkowiak M, Ziętkiewicz E, Witt M. Recent advances in primary ciliary dyskinesia genetics. J Med Genet. 2015 Jan;52(1):1-9. 521 21. Lucas JS, Barbato A, Collins SA, Goutaki M, Behan L, Caudri D, et al. European Respiratory 522 Society guidelines for the diagnosis of primary ciliary dyskinesia. Eur Respir J. 2017 Jan 4;49(1). 523 22. Shapiro AJ, Davis SD, Polineni D, Manion M, Rosenfeld M, Dell SD, et al. Diagnosis of primary 524 525 ciliary dyskinesia. an official american thoracic society clinical practice guideline. Am J Respir Crit Care Med. 2018 Jun 15;197(12):e24-39. 526 527 23. Martin AR, Williams E, Foulger RE, Leigh S, Daugherty LC, Niblock O, et al. PanelApp 528 crowdsources expert knowledge to establish consensus diagnostic gene panels. Nat Genet. 2019 Nov;51(11):1560-5. 529 530 24. Primary ciliary disorders (Version 1.40) [Internet]. [cited 2024 Feb 17]. Available from: 531 https://panelapp.genomicsengland.co.uk/panels/178/. 25. Home - OMIM - NCBI [Internet]. [cited 2024 Feb 17]. Available from: 532 533 https://www.ncbi.nlm.nih.gov/omim 26. Mechaussier S, Dodd DO, Yeyati PL, McPhie F, Attard T, Shoemark A, et al. TUBB4B variants 534 535 specifically impact ciliary function, causing a ciliopathic spectrum. medRxiv. 2022 Oct 21;20. 536 27. Kelley LA, Mezulis S, Yates CM, Wass MN, Sternberg MJE. The Phyre2 web portal for protein 537 modeling, prediction and analysis. Nat Protoc. 2015 Jun;10(6):845-58. 538 28. Zhang K, Foster HE, Rondelet A, Lacey SE, Bahi-Buisson N, Bird AW, et al. Cryo-EM Reveals How Human Cytoplasmic Dynein Is Auto-inhibited and Activated. Cell. 2017 Jun 539 15;169(7):1303-1314.e18. 540 541 29. Guerois R, Nielsen JE, Serrano L. Predicting changes in the stability of proteins and protein 542 complexes: a study of more than 1000 mutations. J Mol Biol. 2002 Jul 5;320(2):369-87. 30. Edgar RC. MUSCLE: multiple sequence alignment with high accuracy and high throughput. 543 544 Nucleic Acids Res. 2004 Mar 19;32(5):1792-7. 545 31. Brown NP, Leroy C, Sander C. MView: a web-compatible database search or multiple 546 alignment viewer. Bioinformatics. 1998;14(4):380-1. Failly M, Bartoloni L, Letourneau A, Munoz A, Falconnet E, Rossier C, et al. Mutations in 547 32. DNAH5 account for only 15% of a non-preselected cohort of patients with primary ciliary 548 dyskinesia. J Med Genet. 2009 Apr;46(4):281-6. 549

Hornef N, Olbrich H, Horvath J, Zariwala MA, Fliegauf M, Loges NT, et al. DNAH5 mutations are
a common cause of primary ciliary dyskinesia with outer dynein arm defects. Am J Respir Crit
Care Med. 2006 Jul 15;174(2):120–6.

- 34. Hagen EM, Sicko RJ, Kay DM, Rigler SL, Dimopoulos A, Ahmad S, et al. Copy-number variant
  analysis of classic heterotaxy highlights the importance of body patterning pathways. Hum
  Genet. 2016 Dec;135(12):1355–64.
- 55635.Tarkar A, Loges NT, Slagle CE, Francis R, Dougherty GW, Tamayo JV, et al. DYX1C1 is required557for axonemal dynein assembly and ciliary motility. Nat Genet. 2013 Sep;45(9):995–1003.
- S6. Knowles MR, Leigh MW, Carson JL, Davis SD, Dell SD, Ferkol TW, et al. Mutations of DNAH11
  in patients with primary ciliary dyskinesia with normal ciliary ultrastructure. Thorax. 2012
  May;67(5):433–41.
- 56137.Guan W-J, Li J-C, Liu F, Zhou J, Liu Y-P, Ling C, et al. Next-generation sequencing for identifying562genetic mutations in adults with bronchiectasis. J Thorac Dis. 2018 May;10(5):2618–30.
- 38. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the
  interpretation of sequence variants: a joint consensus recommendation of the American
  College of Medical Genetics and Genomics and the Association for Molecular Pathology.
  Genet Med. 2015 May;17(5):405–24.
- 567 39. Ellard S. ACGS Best Practice Guidelines for Variant Classification inRare Disease 2020
  568 [Internet]. 2020 [cited 2024 Feb 17]. Available from:
  569 https://www.acgs.uk.com/media/11631/uk-practice-guidelines-for-variant-classification-v4-
- 570 01-2020.pdf
  571 40. Dougherty GW, Loges NT, Klinkenbusch JA, Olbrich H, Pennekamp P, Menchen T, et al.
  572 DNAH11 localization in the proximal region of respiratory cilia defines distinct outer dynein
- 572573arm complexes. Am J Respir Cell Mol Biol. 2016 Aug;55(2):213–24.
- Karczewski KJ, Francioli LC, Tiao G, Cummings BB, Alföldi J, Wang Q, et al. The mutational
  constraint spectrum quantified from variation in 141,456 humans. Nature. 2020 May
  27;581(7809):434–43.
- 42. Boon M, Wallmeier J, Ma L, Loges NT, Jaspers M, Olbrich H, et al. MCIDAS mutations result in
  a mucociliary clearance disorder with reduced generation of multiple motile cilia. Nat
  Commun. 2014 Jul 22;5:4418.
- 43. Wallmeier J, Al-Mutairi DA, Chen C-T, Loges NT, Pennekamp P, Menchen T, et al. Mutations in
  581 CCNO result in congenital mucociliary clearance disorder with reduced generation of multiple
  582 motile cilia. Nat Genet. 2014 Jun;46(6):646–51.
- Fassad MR, Patel MP, Shoemark A, Cullup T, Hayward J, Dixon M, et al. Clinical utility of NGS
  diagnosis and disease stratification in a multiethnic primary ciliary dyskinesia cohort. J Med
  Genet. 2020 May;57(5):322–30.
- 45. Gileles-Hillel A, Mor-Shaked H, Shoseyov D, Reiter J, Tsabari R, Hevroni A, et al. Whole-exome
  sequencing accuracy in the diagnosis of primary ciliary dyskinesia. ERJ Open Research. 2020
  Oct;6(4).
- 589 46. Shamseldin HE, Al Mogarri I, Alqwaiee MM, Alharbi AS, Baqais K, AlSaadi M, et al. An exome-

590 591		first approach to aid in the diagnosis of primary ciliary dyskinesia. Hum Genet. 2020 Oct;139(10):1273–83.
592 593 594	47.	Wheway G, Thomas NS, Carroll M, Coles J, Doherty R, Genomics England Research Consortium, et al. Whole genome sequencing in the diagnosis of primary ciliary dyskinesia. BMC Med Genomics. 2021 Sep 23;14(1):234.
595 596 597	48.	Marshall CR, Scherer SW, Zariwala MA, Lau L, Paton TA, Stockley T, et al. Whole-Exome Sequencing and Targeted Copy Number Analysis in Primary Ciliary Dyskinesia. G3 (Bethesda). 2015 Jul 2;5(8):1775–81.
598 599 600	49.	Belkadi A, Bolze A, Itan Y, Cobat A, Vincent QB, Antipenko A, et al. Whole-genome sequencing is more powerful than whole-exome sequencing for detecting exome variants. Proc Natl Acad Sci USA. 2015 Apr 28;112(17):5473–8.
601 602 603	50.	Kingsmore SF, Cakici JA, Clark MM, Gaughran M, Feddock M, Batalov S, et al. A randomized, controlled trial of the analytic and diagnostic performance of singleton and trio, rapid genome and exome sequencing in ill infants. Am J Hum Genet. 2019 Oct 3;105(4):719–33.
604 605	51.	Hao C, Guo R, Liu J, Hu X, Guo J, Yao Y, et al. Exome sequencing as the first-tier test for pediatric respiratory diseases: A single-center study. Hum Mutat. 2021 Jul;42(7):891–900.
606 607	52.	Halbeisen FS, Pedersen ESL, Goutaki M, Spycher BD, Amirav I, Boon M, et al. Lung function from school age to adulthood in primary ciliary dyskinesia. Eur Respir J. 2022 Oct 20;60(4).
608 609 610	53.	Kuehni CE, Frischer T, Strippoli MPF, Maurer E, Bush A, Nielsen KG, et al. Factors influencing age at diagnosis of primary ciliary dyskinesia in European children. Eur Respir J. 2010 Dec;36(6):1248–58.
611 612	54.	Nogee LM, Ryan RM. Genetic testing for neonatal respiratory disease. Children (Basel). 2021 Mar 11;8(3).
613 614	55.	Machogu E, Gaston B. Respiratory Distress in the Newborn with Primary Ciliary Dyskinesia. Children (Basel). 2021 Feb 18;8(2).
615 616 617	56.	French CE, Delon I, Dolling H, Sanchis-Juan A, Shamardina O, Mégy K, et al. Whole genome sequencing reveals that genetic conditions are frequent in intensively ill children. Intensive Care Med. 2019 May;45(5):627–36.
618 619 620	57.	NICUSeq Study Group, Krantz ID, Medne L, Weatherly JM, Wild KT, Biswas S, et al. Effect of Whole-Genome Sequencing on the Clinical Management of Acutely III Infants With Suspected Genetic Disease: A Randomized Clinical Trial. JAMA Pediatr. 2021 Dec 1;175(12):1218–26.
621 622 623	58.	Farnaes L, Hildreth A, Sweeney NM, Clark MM, Chowdhury S, Nahas S, et al. Rapid whole- genome sequencing decreases infant morbidity and cost of hospitalization. NPJ Genom Med. 2018 Apr 4;3:10.
624 625 626	59.	Petrikin JE, Cakici JA, Clark MM, Willig LK, Sweeney NM, Farrow EG, et al. The NSIGHT1- randomized controlled trial: rapid whole-genome sequencing for accelerated etiologic diagnosis in critically ill infants. NPJ Genom Med. 2018 Feb 9;3:6.
627 628 629	60.	Khalturina EO, Degtyareva ND, Bairashevskaia AV, Mulenkova AV, Degtyareva AV. Modern diagnostic capabilities of neonatal screening for primary immunodeficiencies in newborns. Clin Exp Pediatr. 2021 Oct;64(10):504–10.

20 C1 Develike A Margadia A Tenero CC Discurd C laddens L Al User W. et al. The 2022 undets of

- 630 61. Bousfiha A, Moundir A, Tangye SG, Picard C, Jeddane L, Al-Herz W, et al. The 2022 update of
  631 IUIS phenotypical classification for human inborn errors of immunity. J Clin Immunol. 2022 Oct
  632 6;42(7):1508–20.
- 633 62. Hao Y, Hao S, Andersen-Nissen E, Mauck WM, Zheng S, Butler A, et al. Integrated analysis of 634 multimodal single-cell data. Cell. 2021 Jun 24;184(13):3573-3587.
- 63. Platt CD, Zaman F, Bainter W, Stafstrom K, Almutairi A, Reigle M, et al. Efficacy and economics
  636 of targeted panel versus whole-exome sequencing in 878 patients with suspected primary
  637 immunodeficiency. J Allergy Clin Immunol. 2021 Feb;147(2):723–6.
- 638 64. O'Callaghan C, Chetcuti P, Moya E. High prevalence of primary ciliary dyskinesia in a British
  639 Asian population. Arch Dis Child. 2010 Jan;95(1):51–2.
- 640 65. Hannah WB, Seifert BA, Truty R, Zariwala MA, Ameel K, Zhao Y, et al. The global prevalence
  641 and ethnic heterogeneity of primary ciliary dyskinesia gene variants: a genetic database
  642 analysis. Lancet Respir Med. 2022 May;10(5):459–68.
- 66. O'Connor MG, Mosquera R, Metjian H, Marmor M. CHEST Reviews: Primary Ciliary Dyskinesia.
  644 CHEST Pulmonary. 2023;
- 645 67. NHS England Highly Specialised Services 2020/21 [Internet]. [cited 2024 Feb 17]. Available
  646 from: https://www.england.nhs.uk/wp-content/uploads/2023/11/PRN00328-highly647 specialised-services-2020-2021.pdf
- 648 68. Shoemark A, Griffin H, Wheway G, Hogg C, Lucas JS, Genomics England Research Consortium,
  649 et al. Genome sequencing reveals underdiagnosis of primary ciliary dyskinesia in
  650 bronchiectasis. Eur Respir J. 2022 Nov 17;60(5).
- 69. Shoemark A, Rubbo B, Legendre M, Fassad MR, Haarman EG, Best S, et al. Topological data
  analysis reveals genotype-phenotype relationships in primary ciliary dyskinesia. Eur Respir J.
  2021 Aug 5;58(2).
- Raidt J, Maitre B, Pennekamp P, Altenburg J, Anagnostopoulou P, Armengot M, et al. The
  disease-specific clinical trial network for primary ciliary dyskinesia: PCD-CTN. ERJ Open
  Research. 2022 Jul;8(3).
- ReCode doses first subject in Phase I primary ciliary dyskinesia trial [Internet]. [cited 2024 Feb
  Available from: https://www.clinicaltrialsarena.com/news/recode-primary-ciliarydyskinesia-trial/
- 660 72. Welcome to CFTR2 | CFTR2 [Internet]. [cited 2024 Feb 17]. Available from: https://cftr2.org/
- 73. Mani R, Gomes M, González AR, Hogg C, Morris-Rosendahl D, Maitre B, et al. Development
  and first results of the BEAT-PCD international Primary Ciliary Dyskinesia gene variant
  database: CiliaVar. Paediatric respiratory epidemiology. European Respiratory Society; 2021.
  p. PA3458.
- Aprea I, Nöthe-Menchen T, Dougherty GW, Raidt J, Loges NT, Kaiser T, et al. Motility of
  efferent duct cilia aids passage of sperm cells through the male reproductive system. Mol
  Hum Reprod. 2021 Feb 27;27(3).
- Leung GKC, Mak CCY, Fung JLF, Wong WHS, Tsang MHY, Yu MHC, et al. Identifying the genetic
  causes for prenatally diagnosed structural congenital anomalies (SCAs) by whole-exome

670 sequencing (WES). BMC Med Genomics. 2018 Oct 25;11(1):93.

# High diagnostic rate of whole genome sequencing in primary ciliary dyskinesia

#### **Supplementary Material and Methods**

Holly A Black<sup>1,2</sup>, Sophie Marion de Proce<sup>1\*</sup>, Jose L Campos<sup>3\*</sup>, Alison Meynert<sup>3</sup>, Mihail Halachev<sup>3</sup>, Joseph A Marsh<sup>3</sup>, Robert A Hirst<sup>4</sup>, Chris O'Callaghan<sup>4</sup>, Scottish Genomes Partnership, Javier Santoyo-Lopez<sup>5</sup>, Jennie Murray<sup>2,3</sup>, Kenneth Macleod<sup>6</sup>, Don S Urquhart<sup>6,7</sup>, Stefan Unger<sup>6,7</sup>, Timothy J Aitman<sup>1^</sup>, Pleasantine Mill<sup>3^</sup>

<sup>1</sup> Centre for Genomic and Experimental Medicine, MRC Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK

<sup>2</sup> South East of Scotland Genetics Service, Western General Hospital, Edinburgh, UK

<sup>3</sup> MRC Human Genetics Unit, MRC Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK

<sup>4</sup> Centre for PCD Diagnosis and Research, Department of Respiratory Sciences, University of Leicester, UK

<sup>5</sup> Edinburgh Genomics, Edinburgh, UK

<sup>6</sup> Department of Paediatric Respiratory and Sleep Medicine, Royal Hospital for Sick Children, Edinburgh, UK

<sup>7</sup> Department of Child Life and Health, University of Edinburgh, Edinburgh, UK

\* These authors contributed equally to the manuscript

<sup>^</sup>Joint senior authors

#### SUPPLEMENTARY MATERIALS

Supplementary Table 1: Ranked list of most disruptive reported variants ( $\Delta\Delta G$ ) in the C-terminal domain (CTD) of DNAH11 as predicted by FoldX.  $\Delta\Delta G$  represents the change in free energy by mutation/design of proteins as predicted by the FoldX algorithm, where  $\Delta\Delta G = \Delta G$  fold(mutation) –  $\Delta G$  fold(wild type).

Supplementary Table 2: Genome wide list of variants detected in patient HG-003 by Slivar.

Supplementary File 1: Gene panel used for variant filtering with G2P under a biallelic inheritance model

Supplementary File 2: Gene panel used for variant filtering with G2P under a monoallelic inheritance model

Supplementary File 3 Droplet digital PCR for variant phasing.

Supplementary Video 1: HSVM for cases 1, 2 and 4, which have a genetic diagnosis in *DNAH5*, showing static cilia

Supplementary Video 2: HSVM for cases 7 and 8, which have a genetic diagnosis in DNAH11, showing dysmotile cilia

Supplementary Video 3: HSVM for case 3, showing ciliary agenesis



**Supplementary Figure 1: Principal component analysis (PCA) of study samples compared to 1000 Genomes project samples.** Peddy was used to predict ancestry of the samples used in the study by comparison with the 1000 Genomes samples. The 1000 Genomes samples (dots) are colour-coded by location. The samples in our study are represented by squares. All samples were predicted to be of European ancestry (purple squares), except three (orange squares), which were predicted to have South Asian ancestry. AFR= African; AMR= American; EAS= East Asian; EUR= European; SAS= South Asian.



**Supplementary Figure 2: Alignments of the modelled WES data showing sufficient coverage to call the deletion variants identified in Cases 1, 5 and 6.** A: Alignment for Family 1, showing coverage of exons 32-38 of *DNAH5.* B: Alignment for Family 5, showing coverage of exons 6 to 8 of *DNAAF4.* C: Alignment for Family 6, showing coverage exons 8-10 of *DNAAF4.* 



WGS Alignment- Read Depth

**Supplementary Figure 3: Sanger sequencing confirms 13kb deletion in** *DNAH5* **in Case 1.** Alignments of the WGS data for Family 1 show a drop in read depth to approximately 50% of that of the surrounding regions across a 13kb region of *DNAH5* in the proband and the father. This spans from intron 32 to exon 37. PCR and Sanger sequencing across the breakpoints confirms this deletion. \* indicates the position of the c.5281C>T nonsense variant, which is on the maternal haplotype and is therefore hemizygous in the proband.



Supplementary Figure 4: Drop phase results confirms the two DNAH5 nonsense variants are on different haplotypes for Case 2. The c.3949 variant was assayed using FAM probes and the c.5281 variant was assayed using HEX probes. For each combination of alleles, a representative result from genomic DNA (left) and Pacl-digested DNA (right) is shown. Each figure plots the number of FAM-only positive (blue), HEX-only positive (green), FAM and HEX-positive (orange) and negative (grey) droplets. The linkage % is shown for each test. (Details see Supplementary File 3).

#### SUPPLEMENTARY METHODS

#### Patient cohort

Eight young people with PCD (50% female), aged 6 to 31 years (mean=15, SD= 7.9), were recruited to the study within the Department of Paediatric Respiratory and Sleep Medicine at the Royal Hospital for Sick Children, Edinburgh, and the South East Scotland Genetics service. All eight cases had a confirmed clinical diagnosis of PCD, following TEM and/or HSVM of a nasal brush biopsy sample. The screening and diagnostic testing was performed according to the PCD National Service protocols, with investigations including nNO, nasal brush biopsies analysed by HSVM for ciliary beat frequency and pattern and quantitative electron microscopy for ciliary ultrastructure. Clinical phenotypes are shown in **Table 1**. Blood samples were collected in EDTA tubes from the patients and parents, where available. DNA was extracted using the Chemagic DNA blood kit (Chemagen) or the Nucleon Bacc3 kit (GE Healthcare). Sample ethnicity was assessed using Peddy (v4.0.6) (1) (**Supplementary Figure 1**).

### Gene Panel, sequence data analysis and variant classification

BCBio-Nextgen (0.9.7) was used for alignment and variant detection. This used bwa mem (0.7.13) to align reads to the hg38/GRCh38 reference genome (2), samblaster (0.1.22) to mark duplicate fragments (3) and GATK (3.4-0-g7e26428) for indel realignment and base recalibration (4). GATK HaplotypeCaller was used to calculate genotype likelihoods. Joint genotyping and quality control, including kinship estimates to confirm sample relatedness, were performed using in-house pipelines with GATK (4.0.2.1) following the GATK best practices. Variants were annotated using Ensembl variant effect predictor (VEP 90) (5).

A bespoke gene panel of 146 genes was created (**Supplementary Files 1 and 2**), based on the PCD PanelApp panel (v1.14) and five additional genes identified in the literature (*CFAP300, DNAH6, DNAJB13, STK36* and *TTC25*) (6–8). Variants (SNPs and small indels) were filtered to retain only those within genes on the gene panel and then further filtered to identify candidate variants by inheritance model (both biallelic and monoallelic), transcript consequence, and population allele frequency using the G2P plugin for VEP (9). Variants were assessed using Alamut (v2.13) (10) and classified using the ACMG variant

7

interpretation guidelines (11,12). Any variants classified as pathogenic or likely pathogenic were validated using Sanger sequencing and were submitted to ClinVar. Parental samples were used to determine the phase of compound heterozygous variants, except for Case 2, which used droplet digital PCR (ddPCR) for phasing (**Supplementary File 3**).

SVs were called using Manta (13) and Canvas (version 1.38) (14). The detection of SVs can be challenging and it is common practise to use complementary approaches to detect them (15). Manta detects SVs using discordant paired-end and split reads, whereas Canvas relies on changes in read coverage. We searched for any SVs present in our gene panel that were inherited from either parent. We also searched for de novo SVs for cases where both parents were available. SVs were confirmed *in silico* using SV-Plaudit (16), a tool for rapidly curating SV predictions, and/or using the Integrative Genomics Viewer tool (17). Candidate variants were confirmed in the laboratory by PCR and Sanger sequencing across the deletion breakpoints.

For Case 3, we did not find any diagnostic variants using our gene panel. As *FOXJ1* was only recently identified as a PCD gene and hence was not present on the panel, we searched for SNVs, indels and SVs in Case 3 in this gene, given the ciliary agenesis phenotype observed in this case is associated with *FOXJ1*. We also expanded our analysis for this case to a genome wide search for SNV and small indel candidates with Slivar (0.1.10), following the protocol for rare diseases (<u>https://github.com/brentp/slivar/wiki/rare-disease</u> Date accessed: January 2020). A small number of variants was detected (**Supplementary Table 2**) and none were identified that fitted the current modes of inheritance for PCD.

## Modelling of whole exome sequencing data

A whole exome sequencing (WES)-like subset of the WGS data was obtained by extracting only the reads mapping to the regions in the TWIST Exome Capture Kit (using samtools v1.6) from the BAM file for each sample. The capture region fully covers the exons affected by copy number variants (CNVs) identified based on the WGS data (**Supplementary Figure 2**). The WES CNV calling was performed using ExomeDepth (v 1.1.15) separately on each individual from the three families in which a pathogenic CNV was identified (Families 1, 5).

8

and 6). As controls, we used WES-like subset data from the WGS data for the other samples in this project (total of 21), from which we excluded any members of the family currently being evaluated. As the WGS data was aligned to GRCh38, we generated a custom reference dataset (exons.GRCh38) required by ExomeDepth, to replace the dataset currently distributed with the ExomeDepth package (exons.hg19); exons.GRCh38 is based on the latest CCDS release (r 22) available for the GRCh38 human genome reference (Available at: www.ncbi.nlm.nih.gov/projects/CCDS/CcdsBrowse.cgi?REQUEST=SHOW\_STATISTICS ).

## Homology modelling of DNAH11 and location of missense variants

A homology model of the C-terminal region of the DNAH11 motor domain (residues 3348-4504) was built using PHYRE2 (18), based upon the cryo-electron microscopy structure of human cytoplasmic dynein-1 (PDB ID: 5NUG) (19). The effects of the mutations in the C-terminal domain (CTD) (residues 4124-4504) on protein stability were modelled with FoldX (20), using default parameters and calculated over 10 replicates. Sequences of human dynein genes were aligned with MUSCLE (21) and the sequence alignment was visualised with MView (22).

## SUPPLEMENTARY REFERENCES

- 1. Pedersen BS, Quinlan AR. Who's Who? Detecting and Resolving Sample Anomalies in Human DNA Sequencing Studies with Peddy. Am J Hum Genet. 2017 Mar 2;100(3):406–13.
- 2. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics. 2009 Jul 15;25(14):1754–60.
- 3. Faust GG, Hall IM. SAMBLASTER: fast duplicate marking and structural variant read extraction. Bioinformatics. 2014 Sep 1;30(17):2503–5.
- McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 2010 Sep;20(9):1297–303.
- 5. McLaren W, Gil L, Hunt SE, Riat HS, Ritchie GRS, Thormann A, et al. The ensembl variant effect predictor. Genome Biol. 2016 Jun 6;17(1):122.
- Martin AR, Williams E, Foulger RE, Leigh S, Daugherty LC, Niblock O, et al. PanelApp crowdsources expert knowledge to establish consensus diagnostic gene panels. Nat Genet. 2019 Nov;51(11):1560–5.
- 7. Home OMIM NCBI [Internet]. [cited 2024 Feb 17]. Available from: https://www.ncbi.nlm.nih.gov/omim
- 8. Primary ciliary disorders (Version 1.40) [Internet]. [cited 2024 Feb 17]. Available from: https://panelapp.genomicsengland.co.uk/panels/178/
- Thormann A, Halachev M, McLaren W, Moore DJ, Svinti V, Campbell A, et al. Flexible and scalable diagnostic filtering of genomic variants using G2P with Ensembl VEP. Nat Commun. 2019 May 30;10(1):2373.
- Alamut<sup>™</sup> Visual Plus Variant Annotation and Analysis Software [Internet]. [cited 2024 Feb 18]. Available from: https://www.sophiagenetics.com/platform/alamut-visual-plus/
- Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015 May;17(5):405–24.
- Ellard S. ACGS Best Practice Guidelines for Variant Classification inRare Disease 2020 [Internet]. 2020 [cited 2024 Feb 17]. Available from: https://www.acgs.uk.com/media/11631/uk-practice-guidelines-for-variant-classification-v4-01 -2020.pdf
- Chen X, Schulz-Trieglaff O, Shaw R, Barnes B, Schlesinger F, Källberg M, et al. Manta: rapid detection of structural variants and indels for germline and cancer sequencing applications. Bioinformatics. 2016 Apr 15;32(8):1220–2.
- 14. Ivakhno S, Roller E, Colombo C, Tedder P, Cox AJ. Canvas SPW: calling de novo copy number variants in pedigrees. Bioinformatics. 2018 Feb 1;34(3):516–8.
- 15. Cameron DL, Di Stefano L, Papenfuss AT. Comprehensive evaluation and characterisation of short read general-purpose structural variant calling software. Nat Commun. 2019 Jul

19;10(1):3240.

- Belyeu JR, Nicholas TJ, Pedersen BS, Sasani TA, Havrilla JM, Kravitz SN, et al. SV-plaudit: A cloud-based framework for manually curating thousands of structural variants. Gigascience. 2018 Jul 1;7(7).
- 17. Robinson JT, Thorvaldsdóttir H, Winckler W, Guttman M, Lander ES, Getz G, et al. Integrative genomics viewer. Nat Biotechnol. 2011 Jan;29(1):24–6.
- 18. Kelley LA, Mezulis S, Yates CM, Wass MN, Sternberg MJE. The Phyre2 web portal for protein modeling, prediction and analysis. Nat Protoc. 2015 Jun;10(6):845–58.
- Zhang K, Foster HE, Rondelet A, Lacey SE, Bahi-Buisson N, Bird AW, et al. Cryo-EM Reveals How Human Cytoplasmic Dynein Is Auto-inhibited and Activated. Cell. 2017 Jun 15;169(7):1303-1314.e18.
- 20. Guerois R, Nielsen JE, Serrano L. Predicting changes in the stability of proteins and protein complexes: a study of more than 1000 mutations. J Mol Biol. 2002 Jul 5;320(2):369–87.
- 21. Edgar RC. MUSCLE: multiple sequence alignment with high accuracy and high throughput. Nucleic Acids Res. 2004 Mar 19;32(5):1792–7.
- 22. Brown NP, Leroy C, Sander C. MView: a web-compatible database search or multiple alignment viewer. Bioinformatics. 1998;14(4):380–1.